Some distinctions between flavin-containing and cytochrome P450 monooxygenases

Biochemical and Biophysical Research Communications

Volumn 338, Issue 1, 2005, Pages 599-604

  Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

Author keywords

Amine , sulfide oxygenation; Drug development; Enzyme mechanism; Genetic variation

Indexed keywords

CARBON; DIMETHYLANILINE MONOOXYGENASE; HYDROGEN; NITROGEN; SULFUR; UNSPECIFIC MONOOXYGENASE;

DRUG DETOXIFICATION; DRUG METABOLISM; ENZYME DEGRADATION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENETIC VARIABILITY; HUMAN; HYDROPHILICITY; INFORMATION; LIPOPHILICITY; MATERIALS; METABOLITE; NOMENCLATURE; NONHUMAN; OBSERVATION; OUTPATIENT DEPARTMENT; OXIDATION; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; SPECIES COMPARISON;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; FLAVINS; HUMANS; OXYGENASES;

EID: 27544496636     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.08.009     Document Type: Review

References (49)

1. J.R. Cashman Monoamine oxidase and flavin-containing monooxygenase F.P. Guengerich I.G. Sipes A. McQueen A.J. Gandolfi Comprehensive Toxicology 1997 Pergamon Cambridge 69 96
2. D.M. Ziegler, and C.H. Mitchell Microsomal oxidase IV: properties of mixed-function amine oxidase isolated from pig liver microsomes Arch. Biochem. Biophys. 150 1972 116 125
3. D.M. Ziegler Enzymes adapted for multisubstrate specificity trends Pharmacol. Sci. 11 1990 321 334
4. F.P. Guengerich Cytochrome P450 enzymes F.P. Guengerich I.G. Sipes A. Mc Queen A.J. Gondolfi Comprehensive Toxicology 1997 Pergamon Cambridge 37 68
5. J.R. Cashman Structural and catalytic properties of the mammalian flavin-containing monooxygenase Chem. Res. Toxicol. 8 1995 165 181
6. D. Hernandez, A. Janmohamed, P. Chandan, I.R. Phillips, and E.A. Shephard Organization and evolution of the flavin-containing monooxygenase genes of human and mouse; identification of novel gene and pseudogene clusters Pharmacogenetics 14 2004 117 130
7. R.N. Hines, J.R. Cashman, R.M. Philpot, D.E. Williams, and D.M. Ziegler The mammalian flavin-containing monooxygenase: molecular characterization and regulation of expression Toxicol. Appl. Pharmacol. 125 1994 1 6
8. M. Lawton, J.R. Cashman, T. Cresteil, C. Dolphin, and A. Elfarra A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities Arch. Biochem. Biophys. 308 1994 254 257
9. J.R. Cashman In vitro metabolism: FMO and related oxygenations T.F. Wolfe Handbook of Drug Metabolism 1999 Marcel Dekker Inc. Ann Arbor 477 506
10. J.R. Cashman The implications of polymorphism in mammalian flavin-containing monooxygenases in drug discovery and development Drug Discov. Today 9 2004 574 581
11. D.H. Lang, C.K. Yeung, R.M. Peter, C. Ibarra, and R. Gasser Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3 Biochem. Pharmacol. 56 1998 1005 1012
12. D.H. Lang, and A.E. Rettie In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms Br. J. Clin. Pharmacol. 50 2000 311 314
13. E. Stormer, I. Roots, and J. Brockmoller Benzydamine N-oxygenation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity Br. J. Clin. Pharmacol. 50 2000 553 561
14. J.R. Cashman, S.B. Park, Z.C. Yang, S.A. Wrighton, P. Jacob III, and N. Benowitz Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide Chem. Res. Toxicol. 5 1992 639 646
15. J.R. Cashman, S.B. Park, Z.C. Yang, C.B. Washington, and D.Y. Gomez Chemical, enzymatic, and human enantioselective S-oxygenation of cimetidine Drug Metabol. Dispos. 21 1993 587 597
16. T. Mushiroda, R. Douya, E. Takahara, and O. Nagata The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate Drug Metabol. Dispos. 28 2000 1231 1237
17. J. Fang Metabolism of clozapine by rat brain: the role of flavin-containing monooxygenase(FMO) and cytochrome P450 enzymes Eur. J. Drug Metab. Pharmacokinet. 25 2000 109 114
18. J.H. Kang, W.G. Chung, K.H. Lee, C.S. Park, and J.S. Kang Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FMO3 gene mutations in a Korean population Pharmacogenetics 10 2000 67 78
19. A.E. Rettie, G.P. Meier, and A.J.M. Sadeque Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase Chem. Biol. Interact. 96 1995 3 15
20. S.K. Krueger, D.E. Williams, M.F. Yueh, S.R. Martin, and R.N. Hines Genetic polymorphisms of flavin-containing monooxygenase (FMO) Drug Metab. Rev. 34 2002 523 532
21. D.M. Ziegler An overview of the mechanism, substrate specificities, and structure of FMOs Drug Metab. Rev. 34 2003 503 511
22. D.M. Ziegler Microsomal flavin-containing monooxygenase: oxygenation of nucleophilic nitrogen and sulfur compounds W.B. Jakoby Enzymatic Basis of Detoxication vol. 1 1980 Academic Press New York 201 227
23. D.M. Ziegler Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases Annu. Rev. Pharmacol. Toxicol. 33 1993 179 199
24. G.L. Kedderis, and D.E. Rickert Loss of rat liver microsomal cytochrome P450 during methimazole metabolism. Role of flavin-containing monooxygenase Drug Metab. Dispos. 13 1985 58 61
25. M.A. Cerny, and R.P. Hanzlik Cyclopropylamine inaction of cytochromes P450: role of metabolic intermediate complexes Biochem. Biophys. 436 2005 265 275
26. J.R. Cashman, Y. Xiong, J. Lin, H. Verhagen, and G. van Poppel In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 in the presence of dietary indoles Biochem. Pharmacol. 58 1999 1047 1055
27. B. Clement, M. Weide, and D.M. Ziegler Inhibition of purified and membrane-bound flavin-containing monooxygenase 1 by (N,N-dimethylamino) stillbene carboxylates Chem. Res. Toxicol. 9 1999 599 604
28. D.M. Ziegler, and L.L. Poulson Hepatic mircosomal mixed-function amine oxidase Methods Enzymol. 15 1978 188 193
29. D.M. Ziegler Functional groups bearing sulfur J.R. Bend J. Caldwell W.B. Jakoby Metabolism of Functional Groups 1982 Academic Press New York 171 184
30. J.R. Cashman, K. Camp, S.S. Fakharzadeh, P.V. Fennessey, and R.N. Hines Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria Curr. Drug Metabol. 4 2003 151 170
31. F.J. Gonzalez, and D.W. Nebert Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation Trends Genet. 66 1990 182 186
32. J. Hukkanen, D. Dempsey, P. Jacob III, and N. Benowitz Effect of pregnancy on a measure of FMO3 activity Br. J. Clin. Pharmacol. 60 2005 224 226
33. D.M. Ziegler, and L.L. Poulsen Catalytic mechanism of FMO-catalyzed N- and S-oxidations N. Gooderham Drug Metabolism. Towards the Next Millennium 1998 ISO Press Amsterdam 30 38
34. A. Janmohamed, D. Hernandez, I.R. Phillips, and E.A. Shephard Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenase (FMO's) Biochem. Pharmacol. 68 2004 73 83
35. A. Lusska, E. Shen, and J.P. Whitlock Jr. Protein-DNA interactions at a dioxin-responsive enhancer Analysis of six bona fide DNA-binding sites for the liganded Ah receptor J. Biol. Chem. 268 1993 6575 6580
36. M. Liao, V.G. Zgoda, B.P. Murray, and M.A. Correia Vacuolar degradation of rat liver CYP2B1 in Saccharomyces cerevisiae: further validation of the yeast model and structural implications for the degradation of mammalian endoplasmic reticulum P450 proteins Mol. Pharmacol. 67 2005 1460 1469
37. K.K. Korsmeyer, S. Guan, Z. Yang, A.M. Falick, D.M. Ziegler, and J.R. Cashman N-glycosylation of pig flavin-containing monooxygenase form 1: determination of the site of protein modification by mass spectrometry Chem. Res. Toxicol. 11 1998 1145 1153
38. G.T. Tucker, J.H. Silas, and A.O. Iyun Polymorphic hydroxylation of debrisoquine Lancet 2 1977 718
39. J.A. Goldstein, and S.M. de Morais Biochemistry and molecular biology of the human CYP2C subfamily Pharmacogenetics 4 1994 285 299
40. V. Lattard, J. Zhang, Q. Tran, B. Furnes, D. Schlenk, and J.R. Cashman Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies Drug Metabol. Dispos. 31 2003 854 860
41. J.R. Cashman Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism Pharmacogenomics 3 2002 325 339
42. S.B. Koukouritaki, M.T. Poch, E.T. Cabacungan, D.G. McCarver, and R.N. Hines Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polumorphisms and functional analysis of upstream haplotype variants Mol. Pharmacol. 68 2005 383 392
43. V. Lattard, J. Zhang, and J.R. Cashman Alternative processing events in human FMO genes Mol. Pharmacol. 65 2004 1517 1525
44. L.H. Overby, G.C. Carver, and R.M. Philpot Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans Chem. Biol. Interact. 106 1997 29 45
45. C.K. Yeung, D.H. Lang, K.E. Thummel, and A.E. Rettie Immunoquantitation of FMO1 in human liver, kidney, and intestine Drug Metabol. Dispos. 28 2000 1107 1111
46. E. Mayatepek, B. Flock, and J. Zschocke Benzydamine metabolism in vivo is impaired in patients with deficiency of flavin-containing monooxygenase 3 Pharmacogenetics 14 2004 775 777
47. S.B. Park, P. Jacob III, N.L. Benowitz, and J.R. Cashman Stereoselective metabolism of (S)-(-)-nicotine in humans formation of trans-(S)-(-)-nicotine N-1'-oxide Chem. Res. Toxicol. 6 1993 880 888
48. J.R. Cashman Stereoselectivity in S- and N-oxygenation by the mammalian flavin-containing and cytochrome P-450 monooxygenases Drug Metab. Rev. 30 1998 675 707
49. J.R. Cashman The role of flavin-containing monooxygenases in drug metabolism and development Curr. Opin. Drug Discov. Develop. 6 4 2004 486 493